All articles

Aquiti Closes €60M AVA1 Fund for France's South-West

Date
Read7 min read
Aquiti Closes €60M AVA1 Fund for France's South-West

TL;DR

Aquiti Gestion has reached a final close of nearly €60 million on its AVA1 fund, hitting its target two years after a €30 million first close in 2024. The fund backs pre-seed and seed startups across France's southwest, a swath of the country that runs from Nouvelle-Aquitaine through Pays de la Loire, Occitanie, Centre-Val de Loire, and the former Auvergne region, and it's putting at least 70% of its firepower into health and climate. With 13 investments already made and a 25-to-30-company target over the next four to five years, this is a regional fund with a genuinely national-scale backer list behind it.

Key Takeaways

A two-year build to target, not a rushed close. AVA1 opened with a €30 million first close in 2024 and has taken the full two years to reach nearly €60 million, which is a deliberate, methodical fundraising pace rather than a sign of struggle. Reaching a stated target on schedule, in a French regional fundraising market that's been tighter than usual, is itself worth noting.

The backer list reads like a map of French regional finance. Bpifrance's Fonds National d'Amorçage 3, funded through the France 2030 plan, anchors the fund alongside Nouvelle-Aquitaine's regional investment vehicle, Crédit Mutuel Arkéa, MACSF, and entities tied to both Crédit Agricole and the BPCE banking group. That's a genuinely broad coalition of public and mutualist capital rather than a single sponsor writing most of the check.

Health and climate aren't a side bet, they're the mandate. At least 70% of AVA1's capital is earmarked for health and environment-focused companies, and the fund carries an Article 8 classification under SFDR, Europe's sustainable finance disclosure rules. That's a meaningfully higher sector concentration than most generalist regional funds commit to upfront.

Early checks that actually track the stated thesis. The 13 portfolio companies disclosed so far, spanning a polymer chemistry startup in Mérignac, a care-coordination platform in Bordeaux, a neuropathy treatment company in Limoges, and a retail resale platform in Nantes, line up cleanly with the health-and-climate mandate rather than reading like opportunistic deals bolted on after the fact.

Fund Overview

Fund Name: AVA1 (Aquiti)
Fund Size: Nearly €60 million (final close; €30 million first close in 2024)
Stage: Pre-seed and seed
Check Size: €100,000 to €3 million initially, up to €6 million including follow-on investment
Geography: Nouvelle-Aquitaine, Pays de la Loire, Occitanie, Centre-Val de Loire, and the former Auvergne region (France's southwest quadrant)
Focus: At least 70% to health and environment-focused startups with breakthrough technology or innovative business models; Article 8 SFDR classified
Key LPs: Bpifrance (Fonds National d'Amorçage 3, via France 2030), Région Nouvelle-Aquitaine (through Société Nouvelle-Aquitaine Participations), Crédit Mutuel Arkéa, MACSF, Crédit Agricole and BPCE group entities, regional entrepreneurs and business leaders

Why This Fund Matters

France's venture ecosystem is famously Paris-centric, and regional funds like AVA1 exist specifically to counteract that gravity. Aquiti itself has been doing this for 25 years out of Bordeaux, Limoges, and Poitiers, with roughly €230 million under management or delegated management and a 19-person team, so AVA1 isn't a first-time regional experiment, it's the latest vehicle from a manager with a genuine multi-decade track record of keeping capital and decision-making outside the Paris region.

The geographic footprint is unusually wide for a fund still described as regional. Covering Nouvelle-Aquitaine, Pays de la Loire, Occitanie, Centre-Val de Loire, and the former Auvergne means AVA1 effectively spans a third of mainland France by area, which gives it a far larger addressable deal flow than a single-region fund while still keeping the on-the-ground relationships and due diligence speed that founders value from a local investor.

The LP syndicate is worth dwelling on. Bpifrance's France 2030-backed Fonds National d'Amorçage program exists precisely to mobilize institutional and mutualist capital into early-stage regional funds, and getting Crédit Mutuel Arkéa, MACSF, and entities from both Crédit Agricole and BPCE into the same vehicle is a genuine coordination achievement. It signals that French regional banking and insurance capital sees pre-seed and seed health and climate investing as a legitimate asset-allocation category now, not just a civic-duty checkbox.

The 70% health-and-climate concentration is also a deliberate bet on where Southwest France's research base actually produces deal flow. Bordeaux and the broader region have real strength in health sciences and materials science, and a fund that builds its mandate around that strength, rather than chasing whatever sector is fashionable nationally, tends to see better-quality dealflow simply because it's fishing where the fish are.

The Team

Jean-François Cochy leads AVA1 as Aquiti's Directeur Associé for venture capital, the firm's current title for him on its own team page. Aquiti's broader leadership includes Bérenger Delmas as Président and Régis Lucas as Directeur Général Exécutif, with Thomas Bernard holding the equivalent associate-director role on Aquiti's private equity side. The 19-person team is split across three métiers: Prêt d'Honneur (honor loans), Capital Innovation (the venture arm AVA1 sits within), and Capital Développement & Transmission (growth and transition capital).

Early Portfolio

AVA1 has made 13 investments to date. Named companies include Synbioli, a Mérignac-based developer combining boron chemistry with AI-driven materials modeling; RelaiSanté, a Bordeaux platform coordinating care continuity between hospitals and home-based patients; Curlim, a Limoges company developing treatments for certain forms of peripheral neuropathy; and Speeral, a Nantes-based platform that lets large and specialized retailers resell second-hand products at scale. The fund is targeting 25 to 30 total portfolio companies over its four-to-five-year investment period.

What This Means for Founders

If you're building a health or climate-focused company anywhere across the French southwest, meaning anywhere from Bordeaux to Clermont-Ferrand to Nantes to Toulouse, AVA1 is now a well-capitalized, locally-rooted option that can write a meaningful first check and follow on up to €6 million without forcing you to find a Paris-based lead investor. The fund's explicit Article 8 SFDR classification also means founders working on genuinely sustainability-oriented businesses, rather than companies simply adjacent to the theme, are likely to find a more aligned evaluation process here than with a generalist fund checking an ESG box.

Founders outside the health and climate verticals shouldn't rule AVA1 out entirely, since up to 30% of the fund's capital can go to companies outside that core thesis, but they should expect the health-and-climate deals to get priority attention and faster decision cycles given that's where the fund's underwriting expertise and LP mandate are concentrated.

Fund Momentum Take

What stands out about AVA1 isn't any single number, it's the combination of a patient two-year fundraise, a genuinely broad institutional LP base, and a sector mandate that maps to the region's actual research strengths. That's a harder combination to pull off than it sounds, and a lot of regional funds end up with one or two of those three elements but not all three.

The real test for AVA1 will come over the next 18 to 24 months as it builds out the remaining dozen-plus investments toward its 25-to-30-company target. A 70% sector concentration in health and climate is a strength when the regional deal flow holds up, but it also means the fund has less room to pivot if either vertical underperforms nationally over the life of the fund. Given Aquiti's 25-year track record and the quality of the four named portfolio companies disclosed so far, that looks like a manageable risk rather than a red flag, but it's the one worth watching.

Frequently Asked Questions

How large is the AVA1 fund after its final close?
Nearly €60 million, meeting Aquiti's target two years after a €30 million first close in 2024.

What stage and geography does AVA1 invest in?
Pre-seed and seed-stage companies across France's southwest quadrant: Nouvelle-Aquitaine, Pays de la Loire, Occitanie, Centre-Val de Loire, and the former Auvergne region.

What sectors does the fund focus on?
At least 70% of capital goes to health and environment-focused startups with breakthrough technology or innovative business models. The fund is classified as Article 8 under the EU's Sustainable Finance Disclosure Regulation.

What check sizes does AVA1 write?
Initial investments of €100,000 to €3 million, rising to as much as €6 million including follow-on rounds.

Who are the fund's key backers?
Bpifrance's Fonds National d'Amorçage 3 (funded through France 2030), the Nouvelle-Aquitaine region via its investment vehicle, Crédit Mutuel Arkéa, MACSF, entities from the Crédit Agricole and BPCE banking groups, and regional entrepreneurs and business leaders.


Have a fund closing to announce? Submit your fund here.

Need help raising capital? Check out our Fundraising Advisory services.

Related funds in the index

Digital Health funds from the verified index

FundSizeStageLocationFocus
BlackPeak Southeast Europe Growth Equity Fund II€125M EURGrowthPolandE-Commerce, Digital Health +1
Noctua Science Ventures€15M EURPre SeedAustriaDeep Tech, SaaS +5
NeoSci Ventures (NSV) Fund IS$70M SGDSeedSingaporeBiotech, Digital Health +3
Magnolia MedTech FundNot disclosedSeedNetherlandsDigital Health
Feast VenturesNot disclosedSeedGermanyAgriTech, Digital Health
Search all 950+ VC funds
Share
Connect your agent Free to start. No key, no signup.